These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 30458443)

  • 41. Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation.
    Castagnola E; Mesini A; Saffioti C; Barco S; Bandettini R; Dallorso S; Carrega G; Miano M; Palmisani E; Dufour C
    J Chemother; 2020 Jul; 32(4):217-218. PubMed ID: 32364049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Invasive mould infections in the ICU setting: complexities and solutions.
    Bassetti M; Bouza E
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
    Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
    J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
    Petraitis V; Petraitiene R; Moradi PW; Strauss GE; Katragkou A; Kovanda LL; Hope WW; Walsh TJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2718-26. PubMed ID: 26883703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
    Livermore J; Hope W
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring.
    Davis MR; Chang S; Gaynor P; McCreary EK; Allyn P
    Med Mycol; 2021 Sep; 59(9):939-942. PubMed ID: 34143187
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful Isavuconazole Treatment for Pulmonary Mucormycosis in a Patient Intolerant to Liposomal Amphotericin B with Pharmacokinetic Insights: A Case Report.
    Yasu T; Hoshino M; Sakamoto N; Kobayashi M
    Chemotherapy; 2024 Jun; ():1-6. PubMed ID: 38880094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
    McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
    Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.
    Kontoyiannis DP; Selleslag D; Mullane K; Cornely OA; Hope W; Lortholary O; Croos-Dabrera R; Lademacher C; Engelhardt M; Patterson TF
    J Antimicrob Chemother; 2018 Mar; 73(3):757-763. PubMed ID: 29194488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.
    Kovanda LL; Kolamunnage-Dona R; Neely M; Maertens J; Lee M; Hope WW
    Clin Infect Dis; 2017 Jun; 64(11):1557-1563. PubMed ID: 28472247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of isavuconazole in a patient with voriconazole-induced QTc prolongation.
    Trang TP; Hanretty AM; Langelier C; Yang K
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28434195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.
    Gebremariam T; Alkhazraji S; Baldin C; Kovanda L; Wiederhold NP; Ibrahim AS
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
    Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
    Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A sensitive and validated HPLC-UV method for the quantitative determination of the new antifungal drug isavuconazole in human plasma.
    Nannetti G; Pagni S; Palù G; Loregian A
    Biomed Chromatogr; 2018 Nov; 32(11):e4333. PubMed ID: 29978912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
    Chitasombat MN; Kontoyiannis DP
    Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
    Kovanda LL; Maher R; Hope WW
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Graded isavuconazole introduction in a patient with voriconazole allergy.
    Morales MK; Harris C; Shoham S
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28851131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.